Business Wire

ADVA

30.3.2021 09:02:06 CEST | Business Wire | Press release

Share
ADVA unveils new DCI OLS for the 400ZR era

ADVA (FSE: ADV) today launched its new FSP 3000 data center interconnect (DCI) open line system (OLS) specifically designed for 400ZR technologies. The new DCI OLS addresses the most urgent challenges for network operators by enabling commercial deployments of DCI infrastructure based on 400ZR. These high-density, cost-effective, open solutions that are optimized for point-to-point applications up to 120km will be key to rapidly expanding DCI capacity to meet soaring data demand. Currently undergoing customer testing and evaluation, the ADVA DCI OLS has demonstrated seamless interoperability with 400ZR pluggable transceivers. The solution is fully compliant and even outperforms the 400ZR standard. What’s more, with data center-compatible open APIs, it can be directly integrated into SDN environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005055/en/

“Today we’re announcing a major milestone for open, high-capacity data center networks. The launch of our new DCI OLS will be key for operators. It provides the missing link to real-world deployments of open infrastructure built with 400ZR interfaces,” said Christoph Glingener, CTO, ADVA. “Our pedigree in the DCI space is second to none. We were the original DCI company, enabling Fortune 500 companies around the globe to harness the cloud with best-in-breed solutions. For more than 25 years, our innovation has helped the industry evolve. Now we’re giving large-scale DCI providers what they need to move forward. Our next-generation FSP 3000 DCI OLS offers a way to inject ultra-high capacity while reducing total cost of ownership and operational complexity. What’s more, the ADVA FSP 3000 DCI OLS solution is designed to optimize performance with 400ZR-compliant optics from any vendor.”

The ADVA FSP 3000 DCI OLS is fully compliant with the OIF’s implementation agreement for 400ZR coherent optical interfaces. Optimized for amplified 400Gbit/s DWDM links with reaches up to 120km at 75GHz or 100GHz channel spacing, the solution exceeds all 400ZR performance specifications. It’s also compatible with OpenZR+ interfaces, which expand the application area to DCI applications with distances far beyond 120km. With its open interfaces, the ADVA DCI OLS ensures seamless integration with third-party transceivers and enables network operators to deploy best-of-breed technology. A high level of functional integration minimizes fiber cabling and provides simplified, automated and rapid turnup for optimal performance. The ADVA FSP 3000 DCI OLS integrates multiple diagnostic tools, including built-in OTDR for the monitoring of all fibers and built-in optical channel monitoring. These automated diagnostic capabilities significantly reduce operating costs and improve repair time.

“Omdia is projecting a significant market take-up for 400ZR pluggable technology. 400ZR has many appealing attributes, including multi-vendor interoperability, appealing cost per bit, and a small form factor with low power consumption. Additionally, 400ZR will be practically deployable in switch/routing platforms, enabling the realization of a decades-long service provider dream,” commented Ian Redpath, practice leader, transport networks and components, Omdia. “ADVA has a proven co-development track record in supporting open and innovative DCI solutions. With its new DCI OLS, ADVA is ideally positioned to take the open line system concept to the next level, interworking directly with 400ZR. And with open API support, ADVA will ensure tight integration with cloud and network provider SDN orchestration and control systems.”

Watch this video for more information on the new DCI OLS: https://youtu.be/8zI3E46oMBo .

Further details are also available in these slides: https://adva.li/dci-ols-400zr-slides .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye